Literature DB >> 31081085

Long non-coding RNA DILC as a potentially useful biomarker for the diagnosis and prognosis of colorectal cancer.

Q-G Li1, X-Q Xu, D-Y Zhou, Z-B Jia, B-F Yu, F-G Xu, L Zhang.   

Abstract

OBJECTIVE: LncRNA downregulated in liver cancer stem cells (lnc-DILC) has been implicated as a tumor suppressor in colorectal cancer (CRC). However, the clinical significance of lnc-DILC in CRC patients has not been investigated. In this study, we aimed to explore the diagnostic and prognostic value of lnc-DILC in CRC patients. PATIENTS AND METHODS: The expression of lnc-DILC was measured in 174 paired CRC tissues and adjacent normal tissues using Real Time-Polymerase Chain Reaction (RT-PCR). The correlation of lnc-DILC expression with clinicopathological factors was statistically analyzed by the Chi-square test. Besides, overall survival analysis was carried out with the Kaplan-Meier curve with the log-rank test. Univariate and multivariate analyses were performed to explore the prognostic significance of lnc-DILC expression.
RESULTS: We found that lnc-DILC expression was downregulated in CRC tissues compared to their adjacent normal tissues (p<0.01). ROC analyses showed that lnc-DILC levels were reliable in distinguishing patients with CRC from normal colorectal tissues. Then, down-regulation of lnc-DILC was positively associated with aggressive clinical characteristics, including depth of invasion (p=0.018) and advanced TNM stage (p=0.009). Moreover, the Kaplan-Meier analysis demonstrated that overexpression of lnc-DILC was associated with poorer overall survival (p=0.0205) and disease-free survival (p<0.001). Finally, multivariate analyses confirmed that expression of lnc-DILC was an independent prognostic factor in CRC.
CONCLUSIONS: Our results firstly suggested that lnc-DILC could be a favorable indicator of prognosis in CRC.

Entities:  

Year:  2019        PMID: 31081085     DOI: 10.26355/eurrev_201904_17694

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

1.  LncRNA KCNQ1OT1 acts as miR-216b-5p sponge to promote colorectal cancer progression via up-regulating ZNF146.

Authors:  Shuang Zhu; Chih-Yen Chen; Yangyang Hao
Journal:  J Mol Histol       Date:  2021-01-04       Impact factor: 2.611

2.  LINC01089 Blocks the Proliferation and Metastasis of Colorectal Cancer Cells via Regulating miR-27b-3p/HOXA10 Axis.

Authors:  Ming Li; Xufeng Guo
Journal:  Onco Targets Ther       Date:  2020-08-19       Impact factor: 4.147

Review 3.  Regulatory RNAs, microRNA, long-non coding RNA and circular RNA roles in colorectal cancer stem cells.

Authors:  Hsiao-Mei Chao; Teh-Wei Wang; Edward Chern; Shan-Hui Hsu
Journal:  World J Gastrointest Oncol       Date:  2022-04-15

4.  LINC00665/miR-9-5p/ATF1 is a novel axis involved in the progression of colorectal cancer.

Authors:  Xuhong Zhao; Wenhao Weng; Yin Long; Weijie Pan; Zhi Li; Fenyong Sun
Journal:  Hum Cell       Date:  2020-08-10       Impact factor: 4.174

5.  LncRNA SLCO4A1-AS1 predicts poor prognosis and promotes proliferation and metastasis via the EGFR/MAPK pathway in colorectal cancer.

Authors:  Rui Tang; Junhong Chen; Mengtian Tang; Zhiqiang Liao; Lianqing Zhou; Jiarui Jiang; Yingbin Hu; QianJin Liao; Wei Xiong; Yanyan Tang; Shaolin Nie
Journal:  Int J Biol Sci       Date:  2019-11-08       Impact factor: 6.580

6.  LINC01232 Sponges Multiple miRNAs and Its Clinical Significance in Pancreatic Adenocarcinoma Diagnosis and Prognosis.

Authors:  Wenyan Du; Chengbin Lei; Yanzhen Wang; Yiwen Ding; Peng Tian
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

7.  Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer.

Authors:  Hongxiao Chen; Xiufang Tian; Yajing Luan; Hui Lu
Journal:  Technol Cancer Res Treat       Date:  2019 Jan-Dec

8.  LncRNA SNHG17 Contributes to the Progression of Cervical Cancer by Targeting microRNA-375-3p.

Authors:  Shuping Cao; Hongxia Li; Lei Li
Journal:  Cancer Manag Res       Date:  2021-06-23       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.